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Abstract
Introduction: Although early use of broad-spectrum antimicrobials in critically ill patients may increase
antimicrobial adequacy, uncontrolled use of these agents may select for more-resistant organisms. This study
investigated the effects of early use of broad-spectrum antimicrobials in critically ill patients with hospital-acquired
pneumonia.
Methods: We compared the early use of broad-spectrum antimicrobials plus subsequent de-escalation (DE) with
conventional antimicrobial treatment (non-de-escalation, NDE) in critically ill patients with hospital-acquired
pneumonia (HAP). This open-label, randomized clinical trial was performed in patients in a tertiary-care center
medical intensive care unit (MICU) in Korea. Patients (n = 54) randomized to the DE group received initial
imipenem/cilastatin plus vancomycin with subsequent de-escalation according to culture results, whereas patients
randomized to the NDE group (n = 55) received noncarbapenem, nonvancomycin empiric antimicrobials.
Results: Between November 2004 and October 2006, 109 MICU patients with HAP were enrolled. Initial
antimicrobial adequacy was significantly higher in the DE than in the NDE group for Gram-positive organisms
(100% versus 14.3%; P < 0.001), but not for Gram-negative organisms (64.3% versus 85.7%; P = 0.190). Mean
intensive care unit (ICU) stay, and 14-day, 28-day, and overall mortality rates did not differ in the two groups.
Among culture-positive patients, mortality from methicillin-resistant Staphylococcus aureus (MRSA) pneumonia was
higher in the DE group, even after early administration of vancomycin. Multidrug-resistant organisms, especially
MRSA, were more likely to emerge in the DE group (adjusted hazard ratio for emergence of MRSA, 3.84; 95%
confidence interval, 1.06 to 13.91).
Conclusions: The therapeutic advantage of early administration of broad-spectrum antimicrobials, especially with
vancomycin, was not evident in this study.
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Introduction
Early use of broad-spectrum antimicrobials and subse-
quent de-escalation (DE) after microbiologic culture
results may minimize the emergence of drug-resistant
organisms [1-3] and costs [1] during the treatment of
patients with hospital-acquired pneumonia (HAP). This
strategy may reduce the overall duration of antimicro-
bial treatment [4] and mortality rates [5,6]. These stu-
dies, however, were observational, with successful DE
indicating less-resistant pathogens and/or less severity of
infection.
The combination of carbapenem and vancomycin is
frequently prescribed for the treatment of HAP, in
which the prevalence of infection by multidrug-resistant
(MDR) organisms is high. Although inadequate initial
therapy may increase mortality rates [7], the frequent
use of carbapenem plus vancomycin predisposes to the
emergence of MDR organisms. Vancomycin may select
for resistant pathogens once colonization takes place [8],
and vancomycin use has been associated with increases
in vancomycin-resistant enterococci (VRE) [9] and van-
comycin-intermediate and -resistant S. aureus [10].
Treatment with carbapenems has also been reported to
increase the overall risk for emergence of MDR organ-
isms [11-13]. Moreover, the efficacy of vancomycin as
empiric therapy for HAP in hospitals with a high preva-
lence of methicillin-resistant Staphylococcus aureus
(MRSA) has not been completely addressed. Vancomy-
cin is a relatively large molecule, with poor penetration
into the alveolar lining and alveolar macrophages
[14,15]. In addition, the cure rate for vancomycin in
patients with MRSA pneumonia has been disappointing
[16,17]. A study of febrile neutropenic patients with
MRSA infection showed that these patients did not
experience worse outcomes when vancomycin therapy
was delayed until definitive diagnosis [18]. The use of
carbapenem, which has the broadest spectrum of activity
against Gram-negative organisms, must also be con-
trolled to limit the selection and spread of MDR
pathogens.
To examine these concerns, we conducted a rando-
mized clinical trial in a large tertiary care center in
Korea, where the methicillin resistance rate of S. aureus
isolated from blood has been reported to be 72% [19].
In this trial, we compared the effects of early treatment
with broad-spectrum antimicrobials followed by subse-
quent DE, with conventional antimicrobial regimens.
Materials and methods
Study design
This prospective, open-label, randomized clinical trial
was performed in the 28-bed medical ICU of a 2,200-
bed tertiary care hospital in Seoul, Korea (Asan Medical
Center). Written informed consent was obtained from
each patient or his or her legal guardian. This study was
approved by the institutional review board at Asan Med-
ical Center and was performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki. From November 2004 to October 2006,
patients were randomly assigned to receive either initial
treatment with imipenem/cilastatin plus vancomycin,
with de-escalation starting 3 to 5 days later, based on
initial culture results (de-escalation group, DE), or con-
ventional empiric noncarbapenem antimicrobial therapy
(non-de-escalation group, NDE). The collected data are
described in Additional file 1.
Inclusion and exclusion criteria
Patients were eligible for inclusion if they were older
than 18 years, had been hospitalized > 48 hours, and
had been admitted to the ICU for treatment of estab-
lished HAP. Patients were excluded if their pathogen(s)
had been previously identified, if their antimicrobial
regimen for HAP had been changed > 48 hours before
ICU admission, if they were pregnant or lactating, or if
they had HAP within 1 month before enrollment.
Randomization
After eligibility had been confirmed and consent was
given, patients were randomized 1:1 to the DE or NDE
group, by using an allocation sequence based on a block
size of four, generated by a computer random-number
generator.
Primary and secondary end points
The primary end point was initial antimicrobial ade-
quacy. The secondary end points were mortality, emer-
gence of MDR organisms, duration of antimicrobial
treatment, and ICU stay. To compare the emergence of
MDR organisms in the NDE and DE groups, patients
with initially present MDR organisms were excluded.
Sample size and statistical analysis
Based on a previous study [20], it was expected that the
antimicrobial adequacy would be 48% for NDE and
94.2% for DE. To detect this difference, we calculated
that inclusion of 60 patients per group was required
(two-tailed a = 0.05; 80% power), allowing for 10% drop-
out. Recruitment period of 2 years was planned. We ana-
lyzed a modified intention-to-treat population. Categoric
variables were compared by using the c2 test or the
Fisher Exact test, and continuous variables were com-
pared by using the Student t test. Cox proportional
hazards models were used to calculate hazard ratios
(HRs) and 95% confidence intervals (CIs) for the emer-
gence of MDR organisms with and without de-escalation.
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To determine whether the proportional hazards assump-
tions held, we performed tests based on Schoenfeld resi-
duals. All tests of significance were two-tailed, with P <
0.05 regarded as significant. Data were analyzed by using
Stata version 11.1 (StataCorp, College Station, TX).
Antimicrobial therapy and de-escalation policy
DE patients were treated with imipenem/cilastatin (0.5 g
every 6 hours) and vancomycin (15 mg/kg every 12
hours), with dosages adjusted in patients with renal or
hepatic functional impairment. After 3 to 5 days, imipe-
nem/cilastatin and/or vancomycin were de-escalated
individually, based on culture results and clinical status
(Figure 1). If the organism(s) could not be identified (cul-
ture negative), the treatment was adjusted according to
the day 3 to 5 clinical pulmonary infection score (CPIS)
results. In culture-negative patients with a CPIS > 6 on
day 3 of antimicrobial treatment, the initial antimicrobial
treatment was not de-escalated, and the patient was re-
evaluated for possible etiologic organisms. In culture-
negative patients with CPIS of 6 or less, the initial antimi-
crobial treatment was either discontinued (vancomycin)
or de-escalated (imipenem/cilastatin) [21].
NDE patients received initial antimicrobials empirically
according to the American Thoracic Society (ATS)/
Infectious Diseases Society of America (IDSA) guidelines
for the management of adults with hospital-acquired, ven-
tilator-associated, and healthcare-associated pneumonia
[22], except that none received carbapenem antimicrobials
or vancomycin, and no de-escalation was used. The initial
choice of antimicrobials and all subsequent changes of
regimens, due to antimicrobial inadequacy or treatment
failure, were determined by the attending physician.
Discontinuation of antimicrobial treatment in both
groups was recommended in the absence of purulent
sputum, if WBC was < 10,000/mm3 or decreased > 25%
from its peak value, if body temperature was < 38.3°C, if
improvement or lack of progression appeared on the
chest radiograph, and if the PaO2/FiO2 ratio was > 250
mm Hg [4]. The usual durations of antimicrobial treat-
ment were 7 days for non-MDR organisms, such as
S. aureus and H. influenzae, and 8 to 14 days for MDR
organisms such as Pseudomonas aeruginosa, Acinetobac-
ter baumannii, and MRSA. If clinical improvement was
not evident, the attending physician decided when to
stop antimicrobial treatment [23].
Definitions
HAP was diagnosed according to the American College
of Chest Physicians criteria [22,24], defined as the
Figure 1 Flow algorithm of treatment for patients with hospital-acquired pneumonia in this study.
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occurrence of a new and persistent radiographic infil-
trate occurring 48 hours or more after admission, in
conjunction with two of the following: (a) fever (38.5°C
or higher) or hypothermia (< 36.5°C); (b) leukocytosis
(white blood cells > 10,000/mm3 or < 4,000/mm3); or
(c) purulent tracheal aspirate or sputum. Adequate anti-
microbial treatment was defined as the administration
of one or more antimicrobial agents with in vitro activ-
ity against the bacterial species associated with HAP
[20]. Patients from whom pathogenic microorganisms
could not be isolated from respiratory cultures were
continued on their initial antimicrobial regimen [20].
These patients were considered not evaluable when deter-
mining antimicrobial adequacy and were excluded from
the analysis. MDR organisms included MRSA; vancomy-
cin-resistant enterococci; and certain Gram-negative
bacilli, including those producing extended spectrum
b-lactamase ESBLs; imipenem-resistant Pseudomonas aer-
uginosa; and organisms such as Acinetobacter baumannii,
Stenotrophomonas maltophilia, and Burkholderia cepacia,
which are intrinsically resistant to the broadest-spectrum
antimicrobial agents [8]. Emergence of MDR organisms
was defined as newly isolated MDR organisms during
therapy, after excluding patients with MDR organisms iso-
lated from initial cultures.
Results
Patients
During the 2-year study period, 217 patients were newly
treated for HAP in our ICU. Of these, 108 patients were
excluded because of previously identified pneumonia
pathogens in 49, alterations in the antimicrobial regimen
48 hours or more before ICU admission in 36, refusal to
participate in 18, and for other reasons in five. The
remaining 109 patients were consecutively enrolled, with
108 included in our modified intention-to-treat analysis
(Figure 1).
Table 1 shows a summary of baseline characteristics of
the DE and NDE groups. Of the 109 patients, 88 were
male (80.7%), and 21 were female (19.3%) patients. Their
mean acute physiology and chronic health evaluation
(APACHE) II score was 23.1 (standard deviation [SD], 5.6;
range, 11 to 35). Other parameters did not differ signifi-
cantly in these two groups. Adverse events that occurred
during the study period are listed in Additional file 2.
Organisms identified at the initiation of the study
Initially isolated organisms in both study groups are
shown in Additional file 3. Overall, 54 (50%) patients were
culture positive. Culture methods included bronchoalveo-
lar lavage in 37 patients, endotracheal aspirate in 62,
expectorated sputum in 11, and blood culture in 20. No
significant between-group differences were found in isola-
tion rates of Gram-positive (P = 0.173) and Gram-negative
(P = 0.920) organisms. Gram-positive organisms were
more frequently isolated than were Gram-negative organ-
isms (33.3% versus 26.9%), with MRSA being the single
most frequent organism isolated from patients with HAP
(n = 31; 28.7%).
Initial antimicrobial agents and adequacy
The initial antimicrobial adequacy was significantly higher
in the DE than in the NDE group (75.9% versus NDE,
48%; P = 0.035, Table 2). This was mostly due to the activ-
ity of vancomycin against Gram-positive organisms (P <
0.001 for Gram-positive and P = 0.190 for Gram-negative
organisms). The most frequently prescribed antimicrobial
combination in the NDE group was piperacillin/tazobac-
tam plus ciprofloxacin (63.6%), followed by piperacillin/
tazobactam plus aminoglycoside (20%), and ceftazidime
plus either ciprofloxacin or aminoglycoside (9.1%).
Rate of de-escalation in the DE group, and regimen
change or escalation in the NDE group
We identified 36 patients in the DE group eligible for DE
of vancomycin, and 33 eligible for DE of imipenem/cilasta-
tin. Vancomycin was discontinued in 30 of these 36
patients (83.3%), whereas imipenem/cilastatin was de-esca-
lated in 28 (84.8%) of 33, including DEs to piperacillin/
tazobactam, with or without ciprofloxacin, in 17 patients,
to ceftriaxone in five, to ceftazidime in three, to ampicil-
lin/sulbactam in three, and to cefazolin in two. Of the
patients in the NDE group, 18 underwent change of esca-
lation of their antimicrobial regimen, either to carbapenem
alone (n = 10) or to carbapenem plus vancomycin (n = 8).
Treatment outcomes
The mean (SD) total duration of antimicrobial agents did
not differ significantly in the DE and NDE groups (12.5
[5.8] days versus 14.1 [7.3] days; P = 0.222). In addition, no
significant between-group differences were found in overall
hospital mortality (44.2% versus 34.6%; P = 0.316), day-14
mortality (24.5% versus 13%; P = 0.314), and day-28 mor-
tality (44.2% versus 25.9%; P = 0.131) rates (Table 3). The
mean duration of ICU stay among survivors was longer in
the DE than in the NDE group (21.1 versus 14.1 days), but
the difference was not significant (P = 0.464). Hospital
mortality rates did not differ significantly among patients
with different types of pneumonia, being 40/99 (40.4%) for
patients with HAP and three of nine (33.3%) in patients
with ventilator-associated pneumonia (P > 0.999, data not
shown). Overall, the mortality rates associated with Gram-
positive organisms were higher than those associated with
Gram-negative organisms (Table 4).
Emergence of MDR organisms
In 18 (25.7%) patients, new MDR organisms appeared
within 1 month of antimicrobial treatment, at a mean of
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21 days (range, 9 to 30 days). The overall rate of emer-
gence of MDR organisms was significantly higher in the
DE than in the NDE group (37.9% versus 16.7%; P =
0.043; Table 3), due primarily to the emergence of
MRSA (27.6% versus 9.5%; P = 0.059).
To examine further the association between antimicro-
bial DE and the emergence of MDR organisms, we per-
formed a multivariable analysis adjusting for potential
confounders (Additional file 4). Multivariable-adjusted
hazard ratio (HR) for emergence of MRSA was signifi-
cantly higher with DE than NDE (HR, 3.84; 95% confi-
dence interval (CI), 1.06 to 13.91; P = 0.041). The
adjusted HR for emergence of MDR Gram-negative rods
with DE was lower than NDE (HR, 0.60; 95% CI, 0.17 to
2.07; P = 0.418).
Discussion
This prospective, randomized clinical trial showed that
the adequacy of initial antimicrobial therapy is signifi-
cantly higher with early use of broad-spectrum antimi-
crobials followed by subsequent DE than with it is
conventional therapy. The higher antimicrobial adequacy
observed in the DE group was mainly due to MRSA
coverage by early administration of vancomycin.
Table 1 Baseline characteristics of patients in the DE and NDE groups
Characteristics DE (n = 54)a NDE (n = 55) Pb
Gender 0.772
Male 43 (79.6%) 45 (81.8%)
Female 11 (20.4%) 10 (18.2%)
Age (range), year (IQR) 66.4 (61-77) 61.7 (51-71) 0.117
PaO2/FiO2, mean (SD) 181.8 (103.0) 177.7 (68.1) 0.813
Type of pneumonia > 0.999c
Hospital-acquired pneumonia 50 (92.6%) 50 (90.9%)
Ventilator-associated pneumonia 4 (7.4%) 5 (9.1%)
On mechanical ventilation 47 (50.5%) 46 (49.5%) 0.449
Baseline APACHE II score, mean (SD) 23.3 (5.6) 22.8 (5.7) 0.607
Baseline SOFA score, mean (SD) 9.1 (3.1) 8.4 (3.6) 0.270
Baseline CPIS, mean (SD) 6.7 (1.4) 6.8 (1.3) 0.807
Prior hospital day (IQR)d 16.7 (4-17) 9 (4-10) 0.064
Prior ICU day (IQR)d 4.4 (1-5) 3.4 (1-5) 0.182
Prior ICU days > 5 days 33 (61.1%) 31 (56.4%) 0.416
Prior days on mechanical ventilation (IQR)d 3.3 (0-4) 2.5 (0-4) 0.347
Prior antimicrobial administratione 18 (34.6%) 24 (43.6%) 0.340
Initial presentation 0.943
Severe sepsis 27 (50%) 29 (52.7%)
Septic shock 10 (18.5%) 10 (18.2%)
ARDS 17 (31.5%) 16 (29.1%)
Underlying disease
Hypertension 14 (26.9%) 12 (22.6%) 0.611
Neurologic disease 15 (28.8%) 15 (28.3%) 0.951
COPD 5 (9.6%) 6 (11.3%) > 0.999
Liver cirrhosis 5 (9.6%) 8 (15.1%) 0.555
CRF/ESRD 4 (7.7%) 3 (5.7%) 0.716c
Diabetes mellitus 16 (30.8%) 14 (26.4%) 0.621
Alcoholism 4 (7.7%) 4 (7.5%) > 0.999c
Hematologic malignancy 1 (1.9%) 2 (3.8%) > 0.999c
Modified McCabe score 0.968c
Life expectancy < 1 month 4 (7.5%) 2 (3.6%)
Life expectancy 1 month to 5 years 40 (75.5%) 46 (83.6%)
Life expectancy > 5 years 9 (17%) 7 (12.7%)
Values given as mean (standard deviation) or number (percentage) of patients. ALI, acute lung injury; APACHE, acute physiology and chronic health evaluation;
ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; CPIS, clinical pulmonary infection score; CRF, chronic renal failure; DE,
de-escalation group; ESRD; end-stage renal disease; HAP, hospital-acquired pneumonia; IQR, interquartile range; NDE, non-de-escalation group; SOFA, sequential
organ-failure assessment; VAP, ventilator-associated pneumonia. aClinical outcome of one patient in the DE group was not available. bWith the Student t test or
the c2 test. cWith the Fisher Exact test. dDays before study enrollment in mean (IQR), only including the time spent at Asan Medical Center (Seoul, Republic of
Korea). dPrior administration of antimicrobial agent within 2 days.
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However, no significant between-group differences were
noted in overall duration of antimicrobial therapy and
mortality rates, with the DE group showing a higher
rate of MRSA acquisition. Although vancomycin was
administered early, the mortality associated with MRSA
infections was higher among DE patients. Thus, early
administration of vancomycin failed to show therapeutic
benefits in our study, and early MRSA coverage before
microbiologic documentation seems to be unnecessary.
Early use of broad-spectrum antimicrobials with subse-
quent de-escalation is considered a promising strategy for
optimizing the responsible use of antimicrobials [1]. An
observational study of 398 ICU patients with suspected
VAP reported that the mortality rate was significantly (P =
0.001) lower in patients with DE (17%) than in those with
no change in therapy (23.7%) or escalation (42.6%) [5].
That study, however, was observational, with no randomi-
zation, and other factors, such as baseline disease severity,
may have influenced treatment outcomes, rather than the
DE itself.
Previous studies, however, have reported that DE was
associated with higher antimicrobial adequacy and more
favorable outcomes [6,25-27]. The difference between
these results and ours may be attributable to various fac-
tors. First, our strategy may have improved antimicrobial
adequacy for Gram-positive organisms, most of which
were MRSA. Despite increased antimicrobial adequacy of
vancomycin against Gram-positive organisms in the DE
group, vancomycin had only limited overall efficacy in
the treatment of HAP, with no difference in treatment
outcomes. Moreover, the mortality rate was higher in our
DE than in our NDE group. Vancomycin has been the
only antimicrobial available for the treatment of MRSA
pneumonia for years [14], but its cure rate has been dis-
appointing [16,17]. Also, despite the broad antimicrobial
spectrum of imipenem, its adequacy for Gram-negative
organisms was similar in our DE and NDE groups (64.3%
versus 85.7%; P = 0.19). In a previous study, the adequacy
of treatment for Gram-negative organisms was found to
be higher in patients treated with a DE regimen, in which
the major comparison was between cefotaxime and imi-
penem, which were used in 39% and 100% of NDE and
DE patients, respectively [6]. In contrast, piperacillin/
tazobactam (87.3%) and ciprofloxacin (61.8%) were the
most frequently used initial antimicrobials in our NDE
group. Previous studies have suggested that piperacillin/
Table 3 Treatment outcomes of patients with HAP in the DE and NDE groups
DE (n = 53) NDE (n = 55) Overall (n = 108) P
Time to adequate antimicrobials, days, mean (SD)a 1.9 (0.5) 2.8 (0.6) 2.4 (0.4) 0.280
Mortality
Day 14 13 (24.5%) 9 (16.7%) 22 (20.6%) 0.314
Day 28 21 (39.6%) 14 (25.9%) 35 (32.7%) 0.131
Hospital mortality 23 (44.2%) 18 (34.6%) 41 (39.4%) 0.316
ICU stay, days, mean (IQR)b 21.1 (6-35) 14.1 (6-19) 17.2 (6-19) 0.464c
Emergence of MDR organismsd 11 (37.9%) 7 (16.7%) 18 (25.4%) 0.043
Time to development, days, mean (IQR) 19.4 (11-30) 22.7 (9-30) 21 (11-30) 0.108c
Methicillin-resistant S. aureus 8 (27.6%) 4 (9.5%) 12 (16.9%) 0.059
Gram-negative non-Enterobacteriaceae 4 (13.8%) 5 (11.9%) 9 (12.9%) > 0.999
S. maltophilia 3 (10.7%) 2 (4.8%) 5 (7.1%) 0.383
Imipenem-resistant A. baumannii 0 2 (4.8%) 2 (2.9%) 0.513
Imipenem-resistant P. aeruginosa 0 1 (2.4%) 1 (1.4%) > 0.999
ESBL-producing K. pneumonia 1 (3.6%) 0 1 (2.9%) 0.400
Values given as number (%) of patients, unless otherwise stated. DE, de-escalation group; ESBL, extended spectrum b-lactamase; IQR, inter-quartile range; MDR,
multidrug-resistant; NDE, non-de-escalation group; SD, standard deviation. aTime from initial diagnosis of pneumonia to administration of adequate antimicrobial
agent among initially culture-positive patients. bExcluding patients who died. cWith the Kruskal-Wallis rank test. dMDR organisms isolated within 1 month of study
enrollment. Patients with initial MDR organisms were excluded (24 patients in the DE and 13 in the NDE group). MDR organisms include methicillin-resistant S.
aureus, imipenem-resistant P. aeruginosa, imipenem-resistant A. baumannii, S. maltophilia, and extended-spectrum b-lactamase-producing organisms.
Table 2 Number of patients who received adequate initial empiric antimicrobials in the DE and NDE groupsa
Organism DE NDE Total P b
n/m (%) n/m (%) n/m (%)
All patients 22/29 (75.9) 12/25 (48) 34/54 (63) 0.035
Gram-positive organisms 21/21 (100) 2/14 (14.3) 22/35 (65.7) < 0.001
Gram-negative organisms 9/14 (64.3) 12/14 (85.7) 21/28 (75) 0.190
Values given as number (percentage) of patients. DE, de-escalation group; m, number of patients with isolated organisms; n, number of patients with adequate
initial antimicrobial treatment; NDE, non-de-escalation group. aOnly culture-positive patients were included. bWith c2or the Fisher Exact test.
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tazobactam and imipenem/cilastatin have similar efficacy
and safety profiles [28-30]. Only one patient had ESBL-
producing Enterobacteriaceae, and broad-spectrum anti-
microbials may have different sensitivity patterns at other
centers. In addition, the definition of “de-escalation” dif-
fered among studies, in that most defined DE with regard
to Gram-negative organisms. For example, the activity
spectrum of antimicrobials was ranked against Gram-
negative bacteria, with DE defined as a switch to or dis-
continuation of a drug class with a less-broad spectrum
of coverage [5]. Others have defined de-escalation simi-
larly, by ranking the antimicrobial spectra of these agents
[6,31]. In contrast, imipenem/cilastatin and vancomycin
were de-escalated individually, with the former de-esca-
lated only in patients with Gram-negative organisms.
Categorizing all these definitions by using the single term
“de-escalation” is confusing and may result in divergent
findings.
The strengths of our study include its prospective
design, high initial prevalence of MDR organisms, and
relatively high severity of infection. To our knowledge, this
is the first randomized clinical trial comparing the DE of
imipenem plus vancomycin with that of non-carbapenem,
non-vancomycin in a medical ICU. This study, however,
had several limitations. First, it was performed in a single
center MICU, which may have biased patient selection.
The proportion of patients with VAP was relatively small,
and carbapenems other than imipenem, such as doripe-
nem, may yield different results. Therefore, the generaliz-
ability of this study may be limited. Furthermore, the
baseline prevalence of MDR organisms was higher in the
DE than in the NDE group, which may have influenced
treatment outcomes [32,33]. However, we sought to mini-
mize this effect by excluding these patients from subse-
quent analyses for emergence of MDR organisms.
Moreover, this study was not double-blinded. Indeed, the
attending physicians showed a tendency not to de-escalate.
Nevertheless, the DE rates were relatively high (83.3% for
vancomycin and 84.8% for imipenem/cilastatin). Another
limitation was our inability to identify pathogens in 50% of
our study patients. The percentage of patients who under-
went bronchoalveolar lavage at the time of enrollment was
relatively low; thus, our rate of obtaining adequate speci-
mens was not high. A possibility of cross-contamination
exists as a source of MDR organisms. We also used the
Clinical and Laboratory Standards Institute (CLSI) stan-
dards, rather than the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) standards to define
antimicrobial susceptibility, which may have resulted in a
small difference in the incidence of MDR organisms. In
addition, our secondary end points, including mortality
rates and emergence of MDR organisms, may not have
been sufficiently powered to detect significant differences.
Also, rectal swabs to identify carriers were not routinely
checked. Finally, the dosage of imipenem (2 g/day) may
have been insufficient for patients with Pseudomonas
pneumonia.
Conclusions
Although early use of broad-spectrum antimicrobials
significantly increased initial antimicrobial adequacy,
treatment outcomes were not improved. The therapeutic
advantage with early use of broad-spectrum antimicro-
bials, especially vancomycin, was not evident in this
study. Our results should be considered as hypothesis
generating, as discussed earlier, and additional clinical
research to verify our observations is needed.
Key messages
♦ Although early use of broad-spectrum antimicro-
bial agents significantly increased the initial ade-
quacy against multidrug-resistant pathogens among
critically ill patients with hospital-acquired pneumo-
nia, it failed to improve survival.
♦ Our data suggest that efficacy of early vancomycin
administration is limited, considering that emergence
of MRSA in the de-escalation group was even higher
than that in the non-de-escalation group.
Additional material
Additional file 1: Additional data collection. Additionally collected
data including severity scores and culture specimens.
Additional file 2: Adverse events during the study period. Adverse
events during study period in de-escalation and in non-de-escalation
groups.
Additional file 3: Initially identified organisms associated with
hospital-acquired pneumonia. Differences in initially identified
organisms in de-escalation and in non-de-escalation groups.
Additional file 4: Unadjusted and multivariable-adjusted analysis for
emergence of MDR organisms by using Cox proportional hazards
models. Multivariable Cox proportional hazards models showing
emergence of multidrug-resistant organisms in de-escalation and in non-
de-escalation groups.
Table 4 Hospital mortality relative to initial antimicrobial
adequacy
Adequacy No. of deaths/episodes (%) P
Overall (n = 54) 0.304
Inadequate 6/20 (30%)
Adequate 15/34 (44.1%)
Gram-positive organism (n = 35) 0.476
Inadequate 4/12 (33.3%)
Adequate 12/23 (52.2%)
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